294 related articles for article (PubMed ID: 10852646)
21. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
Schwartz JS; Wang YR; Cleland JG; Gao L; Weiner M; Poole-Wilson PA;
Am J Manag Care; 2003 Jun; 9(6):417-24. PubMed ID: 12816171
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience with lisinopril. Observations on safety and tolerability.
Cameron HA; Higgins TJ
J Hum Hypertens; 1989 Jun; 3 Suppl 1():177-86. PubMed ID: 2550641
[TBL] [Abstract][Full Text] [Related]
23. Perindopril: in congestive heart failure.
Simpson D; Noble S; Goa KL
Drugs; 2002; 62(9):1367-77; discussion 1378-9. PubMed ID: 12076191
[TBL] [Abstract][Full Text] [Related]
24. High dose lisinopril in heart failure: economic considerations.
Ess SM; Lüscher TF; Szucs TD
Cardiovasc Drugs Ther; 2002 Jul; 16(4):365-71. PubMed ID: 12652106
[TBL] [Abstract][Full Text] [Related]
25. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group.
Beller B; Bulle T; Bourge RC; Colfer H; Fowles RE; Giles TD; Grover J; Whipple JP; Fisher MB; Jessup M
J Clin Pharmacol; 1995 Jul; 35(7):673-80. PubMed ID: 7560247
[TBL] [Abstract][Full Text] [Related]
26. Comparison of treatment with lisinopril versus enalapril for congestive heart failure.
Zannad F; van den Broek SA; Bory M
Am J Cardiol; 1992 Oct; 70(10):78C-83C. PubMed ID: 1329478
[TBL] [Abstract][Full Text] [Related]
27. The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial.
Giles TD; Kerut EK; Roffidal LE; Jones R; Given MB; Hutchinson H; Tresznewsky O
Blood Press Monit; 2001 Apr; 6(2):81-4. PubMed ID: 11433128
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
Cleland JG; Thygesen K; Uretsky BF; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L;
Eur Heart J; 2001 Sep; 22(17):1601-12. PubMed ID: 11492990
[TBL] [Abstract][Full Text] [Related]
29. Safety of long-term use of lisinopril for congestive heart failure.
Moyses C; Higgins TJ
Am J Cardiol; 1992 Oct; 70(10):91C-97C. PubMed ID: 1329480
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
31. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
Plosker GL; Sorkin EM
Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
[TBL] [Abstract][Full Text] [Related]
32. Lisinopril versus placebo in older congestive heart failure patients.
Lewis GR
Am J Med; 1988 Sep; 85(3B):48-54. PubMed ID: 2844088
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors: a comparative review.
Raia JJ; Barone JA; Byerly WG; Lacy CR
DICP; 1990 May; 24(5):506-25. PubMed ID: 2188439
[TBL] [Abstract][Full Text] [Related]
34. Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial.
Potter J; Mistri A; Brodie F; Chernova J; Wilson E; Jagger C; James M; Ford G; Robinson T
Health Technol Assess; 2009 Jan; 13(9):iii, ix-xi, 1-73. PubMed ID: 19208305
[TBL] [Abstract][Full Text] [Related]
35. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
Luzier AB; Forrest A; Adelman M; Hawari FI; Schentag JJ; Izzo JL
Am J Cardiol; 1998 Aug; 82(4):465-9. PubMed ID: 9723634
[TBL] [Abstract][Full Text] [Related]
36. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
Davis R; Coukell A; McTavish D
Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
[TBL] [Abstract][Full Text] [Related]
37. Comparison of lisinopril versus placebo for congestive heart failure.
Lewis GR
Am J Cardiol; 1989 Feb; 63(8):12D-16D. PubMed ID: 2537560
[TBL] [Abstract][Full Text] [Related]
38. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation.
Van Den Berg MP; Crijns HJ; Van Veldhuisen DJ; Griep N; De Kam PJ; Lie KI
J Card Fail; 1995 Dec; 1(5):355-63. PubMed ID: 12836710
[TBL] [Abstract][Full Text] [Related]
39. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
[TBL] [Abstract][Full Text] [Related]
40. [Effectiveness of Lisinopril in the treatment of heart failure].
Ruszty L; Nagy A; Szónyi T; Vályi P; Poór F; Takács J; Zalaváry I
Orv Hetil; 2000 Aug; 141(34):1867-72. PubMed ID: 11006711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
